SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 201.15-1.3%Jan 23 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John O'Neill who wrote (23358)7/20/1998 2:27:00 PM
From: Tim  Read Replies (3) of 32384
 
JO - I share your frustration and concern about dilution, however one must pick the lesser of two evils: issue shares or sell the technology (and risk) for royalties (unless there is someone here who wants to argue that Ligand has to much cash). Which is better for shareholders? Is there an alternative strat that you would like pursued? If Ligand taps the market for $xx million to fund a program with potential of $xxx million, isn't there a business case?

At the end of the day, I like the debt option, however I believe there may not be a risk rating high enough for Ligand.

PS - has anyone calculated whether or not Seregan(sp) is anti-dilutative (beyond the period of reasonable Ontak market development)? Many of the crazies on this board assume that the act of issuing shares is automatically dilutative.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News